Abstract 15701: Pharmacodynamics of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With PCSK9 Gain-Of-Function or ApoB Loss-Of-Function Mutations: An Open-Label Extension Study

Michel Krempf,Paul N. Hopkins,Eric Bruckert,Gérald Luc,Shane Lee,Stephen Donahue

Abstract 15701: Pharmacodynamics of Alirocumab in Patients With Autosomal Dominant Hypercholesterolemia Associated With PCSK9 Gain-Of-Function or ApoB Loss-Of-Function Mutations: An Open-Label Extension Study

2018

Michel Krempf
Paul N. Hopkins
Eric Bruckert
Gérald Luc
Shane Lee
Stephen Donahue

Introduction: Causes of autosomal dominant hypercholesterolemia include apolipoprotein B (ApoB) loss-of-function mutations (LoFm) and PCSK9 gain-of-function mutations (GoFm; very rare). Alirocumab ...

Keywords:

in patient
PCSK9
Internal medicine
Medicine
Alirocumab
extension study
Loss function
Endocrinology
Pharmacodynamics
Apolipoprotein B
gene mutation

Correction
Source
Cite
Save
Machine Reading By IdeaReader

References

Citations